Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Pancreatic Neoplasms 27Carcinoma, Non-Small-Cell Lung 15Neoplasms 6Lung Neoplasms 6Cholangiocarcinoma 6Carcinoma, Hepatocellular 5Sarcoma 4Neoplasm Metastasis 4Bone Neoplasms 4Recurrence 3Ovarian Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Histiocytoma, Malignant Fibrous 3Dermatofibrosarcoma 3Biliary Tract Neoplasms 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Sarcoma, Synovial 2Rhabdomyosarcoma 2Neoplasms, Unknown Primary 2Lymphoma, T-Cell 2Lymphoma, B-Cell 2Liposarcoma 2Leiomyosarcoma 2Hodgkin Disease 2Hemangiosarcoma 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2

Interventions

transplatin 1pembrolizumab 1Radiotherapy 1Radiation Dose Hypofractionation 1Radiation 1Platinum 1Gemcitabine 1Cystectomy 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Infiltrating Bladder Urothelial Carcinoma × Gemcitabine × Clear all
NCT02944357 2017-11-17

Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery

Mayo Clinic

Phase NA Withdrawn
Genitourinary

Infiltrating Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡